Journal of Clinical Endocrinology & Metabolism, Vol 50, 734-739, Copyright © 1980 by Endocrine Society

ARTICLES

Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer

JM Goldman, BR Line, RL Aamodt and J Robbins

Radioiodine uptake by thyroid remnants and metastases postthyroidectomy for thyroid cancer is increased by withdrawing thyroid hormone, which raises TSH levels. The minimal withdrawal time for maximal uptake is unknown. Therefore, we performed 33 studies in 27 patients after 2 weeks and again after 4 weeks of T3 withdrawal. We examined cervical (or pulmonary) uptake and whole body scanning at 48 h and whole body retention at 48, 72, and 96 h after radioiodine. In 4 studies, only physiological nonthyroidal activity was seen on both scans. Cervical uptake was low in these 4 studies. Of the remaining 29 studies with thyroid activity on both scans, 4 had high cervical uptakes after 2 weeks, which decreased by 4 weeks to less than 50% of the 2 week value. The same trend was seen in whole body retentions. In 2 studies, the uptake increased at 4 weeks compared to that at 2 weeks, but the change was small and was reflected in whole body retention of only 1 of these subjects. In 23 studies, including 6 with metastatic disease, the individual uptakes and whole body retentions were similar after 2 and 4 weeks. The mean uptakes and retentions also did not differ despite significantly higher (P less than 0.001) TSH values at 4 weeks. All definite areas of localization of radioactivity seen on the scans after 4 weeks were seen after 2 weeks. Therefore, radioiodine uptake, scanning, and therapy should be performed after 2 weeks of T3 withdrawal when patients are minimally hypothyroid. Serum TSH should also be measured to identify the rare individual not responding to brief T3 withdrawal.

This article has been cited by other articles:

				W. J. Kuijt and S. A. Huang Children with Differentiated Thyroid Cancer Achieve Adequate Hyperthyrotropinemia within 14 Days of Levothyroxine Withdrawal J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6123 - 6125. [Abstract] [Full Text] [PDF]

				D. I. Serhal, M. P. Nasrallah, and B. M. Arafah Rapid Rise in Serum Thyrotropin Concentrations after Thyroidectomy or Withdrawal of Suppressive Thyroxine Therapy in Preparation for Radioactive Iodine Administration to Patients with Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3285 - 3289. [Abstract] [Full Text] [PDF]

				C. S. Bal, A. Kumar, and G. S. Pant Radioiodine Dose for Remnant Ablation in Differentiated Thyroid Carcinoma: A Randomized Clinical Trial in 509 Patients J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1666 - 1673. [Abstract] [Full Text] [PDF]

				P. W. Grigsby, B. A. Siegel, S. Bekker, W. E. Clutter, and J. F. Moley Preparation of Patients with Thyroid Cancer for 131I Scintigraphy or Therapy by 1-3 Weeks of Thyroxine Discontinuation J. Nucl. Med., April 1, 2004; 45(4): 567 - 570. [Abstract] [Full Text] [PDF]

				G. Vitale, G. A. Lupoli, A. Ciccarelli, A. Lucariello, M. R. Fittipaldi, F. Fonderico, A. Panico, and G. Lupoli Influence of Body Surface Area on Serum Peak Thyrotropin (TSH) Levels after Recombinant Human TSH Administration J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1319 - 1322. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				M. Luster, M. Lassmann, H. Haenscheid, U. Michalowski, C. Incerti, and C. Reiners Use of Recombinant Human Thyrotropin before Radioiodine Therapy in Patients with Advanced Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3640 - 3645. [Abstract] [Full Text]

				S.-S. Koong, J. C. Reynolds, E. G. Movius, A. M. Keenan, K. B. Ain, M. C. Lakshmanan, and J. Robbins Lithium as a Potential Adjuvant to 131I Therapy of Metastatic, Well Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 912 - 916. [Abstract] [Full Text]

				M. J. Schlumberger Papillary and Follicular Thyroid Carcinoma N. Engl. J. Med., January 29, 1998; 338(5): 297 - 306. [Full Text] [PDF]

				P. W. Ladenson, L. E. Braverman, E. L. Mazzaferri, F. Brucker-Davis, D. S. Cooper, J. R. Garber, F. E. Wondisford, T. F. Davies, L. J. DeGroot, G. H. Daniels, et al. Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma N. Engl. J. Med., September 25, 1997; 337(13): 888 - 896. [Abstract] [Full Text] [PDF]

				C. H. Emerson and R. Colzani Epithelial Cell Thyroid Cancer and Thyroid Stimulating Hormone--When Less is More J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 9 - 10. [Full Text] [PDF]